Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphoma
NCT03631862Phase 4Unknown
- Sponsor
- Zhengzhou University
- Start
- Sep 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Rivoceranib in peripheral T-cell lymphoma (PTCL) (2 arms), sponsored by Zhengzhou University. Primary endpoints: Progression-Free Survival at 24 months and Response Rate at 18 weeks. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT03631862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03631862.